New vaccine strategy aims to protect spleenless patients from deadly meningitis
NCT ID NCT04166656
First seen Nov 20, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study tests three different schedules of the meningococcal B vaccine in 84 adults aged 18 to 75 who have had their spleen removed. People without a spleen are at higher risk for severe infections. The goal is to find which vaccine strategy produces the strongest immune response to prevent this potentially fatal disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENECTOMY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
I-REIVAC/CIC1417 Cochin Hospital, AP-HP
RECRUITINGParis, 75014, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.